JEFFREY S. HACKMAN
Jeff brings 30 years' commercial pharmaceutical experience, including extensive expertise gained in the oncology field. He joins EUSA from rare disease company Novelion Therapeutics, where he was acting CEO. Prior to this he was Senior VP and Head of US Internal Medicine / Oncology at Shire Inc. Previously, he was responsible for establishing the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He also held senior roles in a number of other pharmaceutical companies.